Arvinas Current Ratio 2017-2021 | ARVN

Arvinas current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Arvinas Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.63B $0.04B 15.01
2021-03-31 $0.67B $0.04B 16.46
2020-12-31 $0.70B $0.05B 14.32
2020-09-30 $0.26B $0.04B 6.53
2020-06-30 $0.25B $0.03B 7.40
2020-03-31 $0.27B $0.03B 8.15
2019-12-31 $0.29B $0.03B 8.87
2019-09-30 $0.20B $0.03B 6.79
2019-06-30 $0.16B $0.02B 7.79
2019-03-31 $0.18B $0.02B 8.73
2018-12-31 $0.20B $0.02B 8.52
2018-09-30 $0.10B $0.02B 4.81
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.04B $0.01B 3.72
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.178B $0.022B
Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76